Actas de congresos
Allogeneic Hematopoietic Stem Cell Transplantation In Chronic Myeloid Leukemia - Current Concepts And Brazilian Experience
Registro en:
Revista Brasileira De Hematologia E Hemoterapia. , v. 30, n. SUPPL. 2, p. 30 - 32, 2008.
15168484
10.1590/S1516-84842008000600008
2-s2.0-55949091170
Autor
De Souza C.A.
Institución
Resumen
Allogeneic Stem Cell Transplantation (ASCT) remains the unique curative therapy for CML in all clinical phases of the disease. However, the results of Imatinib Mesilate (IM) therapy are sufficiently impressive to have displaced ASCT to second- or third-line treatment depending on the availability of newly developed tyrosine kinase inhibitors. The decision for transplantation depends on a variety of clinical and biological situations. The Leukemia Net recommendations as well the NCCN guidelines help us to choose the best moment to perform ASCT. In 1998, Gratwohl and colleagues published a score in order to establish the risk of ASCT before the procedure. In 2005, the Brazilian group, studying more than 1000 patients in an independent population, validated the risk score previously proposed by the EBMT Group. In this paper we discuss the position of ASCT in a country such as Brazil that presents resource limitations. In 2006, the EBMT published an activity survey about ASCT in CML and discussed the changes in treatment indications over the past 15 years and presented differences in medical conduct in West versus East Europe concerning ASCT indication. Despite of risks, ASCT remains a valid curative treatment. To delay or to perform the ASCT in advanced phases (accelerated- or blastic-phase) increases procedure-related mortality rates and reduces the probability of cure. 30 SUPPL. 2 30 32 Goldman, J.M., Druker, B.J., Chronic myeloid leukemia: Current treatment options (2001) Blood, 98 (7), pp. 2039-2042 Goldman, J.M., Therapeutic strategies for chronic myeloid leukemia in the chronic (stable) phase (2003) Semin Hematol, 40, pp. 10-17 Goldman, J.M., Marin, D., Management decisions in chronic myeloid leukemia (2003) Semin Hematol, 40 (1 SUPPL. 1), pp. 10-17 Goldman, J.M., Marin, D., Olavarria, E., Apperley, J.F., Clinical decisions for chronic myeloid leukemia in the imatinib era (2003) Semin Hematol, 40 (2 SUPPL. 2), pp. 98-103 Deininger, M.W., O'Brien, S.G., Ford, J.M., Druker, B.J., Practical management of patients with chronic myeloid leukemia receiving imatinib (2003) J Clin Oncol, 21 (8), pp. 1637-1647 Peggs, K., Mackinnon, S., Imatinib mesylate - the new gold standard for treatment of chronic myeloid leukemia (2003) N Engl J Med, 348 (11), pp. 1048-1050 Druker, B.J., Sawyers, C.L., Kantarjian, H., Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome (2001) N Engl J Med, 344 (14), pp. 1038-1042 Kantarjian, H., Sawyers, C., Hochhaus, A., Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia (2002) N Engl J Med, 346 (9), pp. 645-652 Talpaz, M., Silver, R.T., Druker, B.J., Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: Results of a phase 2 study (2002) Blood, 99 (6), pp. 1928-1937 Sawyers, C.L., Hochhaus, A., Feldman, E., Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: Results of a phase II study (2002) Blood, 99 (10), pp. 3530-3539 O'Brien, S.G., Guilhot, F., Larson, R.A., Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia (2003) N Engl J Med, 348 (11), pp. 994-1004 Hughes, T.P., Kaeda, J., Branford, S., Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia (2003) N Engl J Med, 349 (15), pp. 1423-1432 Bhatia, R., Holtz, M., Niu, N., Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment (2003) Blood, 101 (12), pp. 4701-4707 Gorre, M.E., Mohammed, M., Ellwood, K., Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification (2001) Science, 293 (5531), pp. 876-880 Shah, N.P., Nicoll, J.M., Nagar, B., Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia (2002) Cancer Cell, 2 (2), pp. 117-125 Branford, S., Rudzki, Z., Walsh, S., High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance (2002) Blood, 99 (9), pp. 3472-3475 Hochhaus, A., Kreil, S., Corbin, A.S., Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy (2002) Leukemia, 16 (11), pp. 2190-2196 Branford, S., Rudzki, Z., Walsh, S., Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis (2003) Blood, 102 (1), pp. 276-283 Thomas, E.D., Clift, R.A., Fefer, A., Marrow transplantation for the treatment of chronic myelogenous leukemia (1986) Ann Intern Med, 104 (2), pp. 155-163 Goldman, J.M., Apperley, J.F., Jones, L., Bone marrow transplantation for patients with chronic myeloid leukemia (1986) N Engl J Med, 314 (4), pp. 202-207 Barrett, A.J., Malkovska, V., Graft-versus-leukaemia: Understanding and using the alloimmune response to treat haematological malignancies (1996) Br J Haematol, 93 (4), pp. 754-761 Passweg, J.R., Walker, I., Sobocinski, K.A., Klein, J.P., Horowitz, M.M., Giralt, S.A., Validation and extension of the EBMT Risk Score for patients with chronic myeloid leukaemia (CML) receiving allogeneic haematopoietic stem cell transplants (2004) Br J Haematol, 125 (5), pp. 613-620 Gratwohl, A., Hermans, J., Goldman, J.M., Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (1998) Lancet, 352 (9134), pp. 1087-1092 De Souza, C.A., Vigorito, A.C., Ruiz, M.A., Validation of the EBMT risk score in chronic myeloid leukemia in Brazil and allogeneic transplant outcome (2005) Haematologica, 90 (2), pp. 232-237 Gratwohl, A., Baldomero, H., Frauendorfer, K., Urbano-Ispizua, A., EBMT activity survey 2004 and changes in disease indication over the past 15 years (2006) Bone Marrow Transplant, 37 (12), pp. 1069-1085